Literature DB >> 11454057

Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells.

T Ohkawa1, S Seki, H Dobashi, Y Koike, Y Habu, K Ami, H Hiraide, I Sekine.   

Abstract

We investigated the function of CD56+ CD8+ T cells (CD56+ T cells) and CD56- CD57+ CD8+ T cells (CD57+ T cells; natural killer (NK)-type T cells) and compared them with those of normal CD56- CD57- CD8+ T cells (CD8+ T cells) and CD56+ NK cells from healthy volunteers. After the stimulation with immobilized anti-CD3 antibodies, both NK-type T cells produced much larger amounts of interferon-gamma (IFN-gamma) than CD8+ T cells. Both NK-type T cells also acquired a more potent cytotoxicity against NK-sensitive K562 cells than CD8+ T cells while only CD56+ T cells showed a potent cytotoxicity against NK-resistant Raji cells. After the stimulation with a combination of interleukin (IL)-2, IL-12 and IL-15, the IFN-gamma amounts produced were NK cells > or = CD56+ T cells > or = CD57+ T cells > CD8+ T cells. The cytotoxicities against K562 cells were NK cells > CD56+ T cells > or = CD57+ T cells > CD8+ T cells while cytotoxicities against Raji cells were CD56+ T cells > CD57+ T cells > or = CD8+ T cells > or = NK cells. However, the CD3-stimulated proliferation of both NK-type T cells was smaller than that of CD8+ T cells partly because NK-type T cells were susceptible to apoptosis. In addition to NK cells, NK-type T cells but not CD8+ T cells stimulated with cytokines, expressed cytoplasmic perforin and granzyme B. Furthermore, CD3-stimulated IFN-gamma production from peripheral blood mononuclear cells (PBMC) correlated with the proportions of CD57+ T cells in PBMC from donors. Our findings suggest that NK-type T cells play an important role in the T helper 1 responses and the immunological changes associated with ageing.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454057      PMCID: PMC1783250          DOI: 10.1046/j.1365-2567.2001.01248.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  51 in total

1.  Analysis of mechanisms by which NK cells acquire increased cytotoxicity against class I MHC-eliminated targets.

Authors:  S Sugawara; T Abo; H Itoh; K Kumagai
Journal:  Cell Immunol       Date:  1989-04-01       Impact factor: 4.868

Review 2.  Extrathymic pathways of T-cell differentiation in the liver and other organs.

Authors:  T Abo; H Watanabe; T Iiai; M Kimura; K Ohtsuka; K Sato; M Ogawa; H Hirahara; S Hashimoto; H Sekikawa
Journal:  Int Rev Immunol       Date:  1994       Impact factor: 5.311

3.  Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells.

Authors:  A S Stern; F J Podlaski; J D Hulmes; Y C Pan; P M Quinn; A G Wolitzky; P C Familletti; D L Stremlo; T Truitt; R Chizzonite
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

4.  Diminished calcium signal generation in subsets of T lymphocytes that predominate in old mice.

Authors:  B Philosophe; R A Miller
Journal:  J Gerontol       Date:  1990-05

5.  The age-associated increase in IFN-gamma synthesis by mouse CD8+ T cells correlates with shifts in the frequencies of cell subsets defined by membrane CD44, CD45RB, 3G11, and MEL-14 expression.

Authors:  D N Ernst; W O Weigle; D J Noonan; D N McQuitty; M V Hobbs
Journal:  J Immunol       Date:  1993-07-15       Impact factor: 5.422

6.  Increased percentage of CD3+, CD57+ lymphocytes in patients with rheumatoid arthritis. Correlation with duration of disease.

Authors:  A Dupuy d'Angeac; S Monier; C Jorgensen; Q Gao; A Travaglio-Encinoza; C Bologna; B Combe; J Sany; T Rème
Journal:  Arthritis Rheum       Date:  1993-05

7.  Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor.

Authors:  K H Grabstein; J Eisenman; K Shanebeck; C Rauch; S Srinivasan; V Fung; C Beers; J Richardson; M A Schoenborn; M Ahdieh
Journal:  Science       Date:  1994-05-13       Impact factor: 47.728

8.  Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.

Authors:  M Kobayashi; L Fitz; M Ryan; R M Hewick; S C Clark; S Chan; R Loudon; F Sherman; B Perussia; G Trinchieri
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

9.  Purified perforin induces target cell lysis but not DNA fragmentation.

Authors:  R C Duke; P M Persechini; S Chang; C C Liu; J J Cohen; J D Young
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

10.  An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans.

Authors:  O Lantz; A Bendelac
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  42 in total

Review 1.  The transcriptional control of the perforin locus.

Authors:  Matthew E Pipkin; Anjana Rao; Mathias G Lichtenheld
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

Review 2.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

3.  Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.

Authors:  Richard C Wu; Shujuan Liu; Jessica A Chacon; Sheng Wu; Yufeng Li; Pariya Sukhumalchandra; James L Murray; Jeffrey J Molldrem; Patrick Hwu; Hanspeter Pircher; Gregory Lizée; Laszlo G Radvanyi
Journal:  Clin Cancer Res       Date:  2012-02-03       Impact factor: 12.531

4.  Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models.

Authors:  Denise L Crossland; Warren L Denning; Sonny Ang; Simon Olivares; Tiejuan Mi; Kirsten Switzer; Harjeet Singh; Helen Huls; Kate S Gold; Bonnie S Glisson; Laurence J Cooper; John V Heymach
Journal:  Oncogene       Date:  2018-04-06       Impact factor: 9.867

5.  Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders.

Authors:  H Veenstra; R Baumann; N M Carroll; P T Lukey; M Kidd; N Beyers; C T Bolliger; P D van Helden; G Walzl
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

Review 6.  CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease.

Authors:  Marius Strioga; Vita Pasukoniene; Dainius Characiejus
Journal:  Immunology       Date:  2011-06-29       Impact factor: 7.397

7.  Fine phenotypic and functional characterization of effector cluster of differentiation 8 positive T cells in human patients with primary biliary cirrhosis.

Authors:  Masanobu Tsuda; Yoko M Ambrosini; Weici Zhang; Guo-Xiang Yang; Yugo Ando; Guanghua Rong; Koichi Tsuneyama; Kosuke Sumida; Shinji Shimoda; Christopher L Bowlus; Patrick S C Leung; Xiao-Song He; Ross L Coppel; Aftab A Ansari; Zhe-Xiong Lian; M Eric Gershwin
Journal:  Hepatology       Date:  2011-10       Impact factor: 17.425

8.  Characterization of bronchoalveolar lavage T cell subsets in sarcoidosis on the basis of CD57, CD4 and CD8.

Authors:  T Kurumagawa; S Seki; H Kobayashi; Y Koike; S Kanoh; H Hiraide; K Motoyoshi
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

9.  Upregulation of SOCS-3 and PIAS-3 impairs IL-12-mediated interferon-gamma response in CD56 T cells in HCV-infected heroin users.

Authors:  Li Ye; Xu Wang; David S Metzger; Eric Riedel; Luis J Montaner; Wenzhe Ho
Journal:  PLoS One       Date:  2010-03-09       Impact factor: 3.240

10.  Activation of human T cells with NK cell markers by staphylococcal enterotoxin A via IL-12 but not via IL-18.

Authors:  K Ami; T Ohkawa; Y Koike; K Sato; Y Habu; T Iwai; S Seki; H Hiraide
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.